MorphoSys AG
FRANKFURT : MOR

August 26, 2013 08:13 ET

MorphoSys Announces Presentations at Upcoming Investor Conferences

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - Aug 26, 2013) -

MorphoSys AG / MorphoSys Announces Presentations at Upcoming Investor Conferences.

Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at five upcoming international investor conferences:

Commerzbank Sector Conference Week

Date: August 27, 2013, 10:45am CEST (9:45am BST, 4:45am EDT)

Venue: Frankfurt, Germany

Participants:

Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR


Morgan Stanley Global Healthcare Conference

Date: September 9, 2013, 2:25pm EDT (7:25pm BST, 8:25pm CEST)

Venue: New York, USA

Participants:

Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Jens Holstein, Chief Financial Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR


Bank of America Merrill Lynch Global Healthcare Conference 2013

Date: September 11, 2013, 3.30pm BST (10:30am EDT, 4:30pm CEST)

Venue: London, UK

Participants:

Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR


Berenberg and Goldman Sachs Second German Corporate Conference

Date: September 24, 2013, 1:45pm CEST (12:45pm BST, 7:45am EDT)

Venue: Munich, Germany

Participants:

Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Jens Holstein, Chief Financial Officer of MorphoSys AG

Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR


Baader Investment Conference 2013

Date: September 24, 2013, 9:00am CEST (8:00am BST, 3:00am EDT)

Venue: Munich, Germany

Participants:

Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Jens Holstein, Chief Financial Officer of MorphoSys AG

Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR


The PDF version of the presentation will be provided at www.morphosys.com. The link to the webcasts will be filed under www.morphosys.com/conference-calls.


About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG. Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF): http://hugin.info/130295/R/1724790/575001.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1724790]

Contact Information

  • For more information, please contact:
    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Associate Director Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Alexandra Goller
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact